share_log

Insider Buying: Indaptus Therapeutics, Inc. (NASDAQ:INDP) CEO Buys $18,240.00 in Stock

kopsource ·  Nov 25, 2022 21:51

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) CEO Jeffrey A. Meckler bought 9,600 shares of the company's stock in a transaction that occurred on Monday, November 21st. The stock was purchased at an average price of $1.90 per share, for a total transaction of $18,240.00. Following the transaction, the chief executive officer now owns 75,374 shares of the company's stock, valued at $143,210.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Indaptus Therapeutics Stock Performance

Indaptus Therapeutics stock opened at $1.80 on Friday. Indaptus Therapeutics, Inc. has a 12 month low of $1.64 and a 12 month high of $7.10. The stock's 50 day simple moving average is $2.00 and its two-hundred day simple moving average is $2.43.

Get Indaptus Therapeutics alerts:

Institutional Investors Weigh In On Indaptus Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Northern Trust Corp purchased a new stake in Indaptus Therapeutics in the 1st quarter worth approximately $41,000. State Street Corp purchased a new stake in Indaptus Therapeutics in the 1st quarter worth approximately $78,000. Renaissance Technologies LLC purchased a new stake in Indaptus Therapeutics in the 2nd quarter worth approximately $51,000. Vanguard Group Inc. boosted its position in Indaptus Therapeutics by 18.7% in the 1st quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock worth $969,000 after purchasing an additional 38,216 shares in the last quarter. Finally, Strategy Asset Managers LLC purchased a new stake in Indaptus Therapeutics in the 3rd quarter worth approximately $120,000. Hedge funds and other institutional investors own 19.25% of the company's stock.

Indaptus Therapeutics Company Profile

(Get Rating)

Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.

Further Reading

  • Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
  • Microsoft Shares: Is it Time to Back Up the Truck?
  • Institutional Support for Analog Devices Remains High
  • Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
  • Is the 60/40 Portfolio Mix Still in Vogue?
  • Three CBD Stocks to Dominate a Budding Industry

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment